Business Description
Lisata Therapeutics Inc
NAICS : 325414
SIC : 8099
ISIN : US1280582032
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 217.4 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 44.6 | |||||
3-Year EPS without NRI Growth Rate | 29 | |||||
3-Year FCF Growth Rate | 33.9 | |||||
3-Year Book Growth Rate | -38.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 17.67 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.13 | |||||
9-Day RSI | 47.15 | |||||
14-Day RSI | 48.56 | |||||
6-1 Month Momentum % | 4 | |||||
12-1 Month Momentum % | 28.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.42 | |||||
Quick Ratio | 9.42 | |||||
Cash Ratio | 8.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -84.8 | |||||
Shareholder Yield % | 1.2 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -43.84 | |||||
ROA % | -39.61 | |||||
ROIC % | -2481.11 | |||||
3-Year ROIIC % | 14489.21 | |||||
ROC (Joel Greenblatt) % | -13747.43 | |||||
ROCE % | -50.22 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.63 | |||||
Price-to-Tangible-Book | 0.63 | |||||
EV-to-EBIT | 0.58 | |||||
EV-to-EBITDA | 0.58 | |||||
EV-to-FCF | 0.7 | |||||
Price-to-Net-Current-Asset-Value | 0.64 | |||||
Price-to-Net-Cash | 0.71 | |||||
Earnings Yield (Greenblatt) % | 172.41 | |||||
FCF Yield % | -82.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Lisata Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.379 | ||
Beta | 0.56 | ||
Volatility % | 38.57 | ||
14-Day RSI | 48.56 | ||
14-Day ATR (€) | 0.081218 | ||
20-Day SMA (€) | 2.637 | ||
12-1 Month Momentum % | 28.71 | ||
52-Week Range (€) | 1.88 - 3.34 | ||
Shares Outstanding (Mil) | 8.32 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lisata Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lisata Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Lisata Therapeutics Inc Frequently Asked Questions
What is Lisata Therapeutics Inc(STU:8NE)'s stock price today?
When is next earnings date of Lisata Therapeutics Inc(STU:8NE)?
Does Lisata Therapeutics Inc(STU:8NE) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |